- Home
- KAVL vs KPRX Comparison
KAVL vs KPRX Comparison
Compare KAVL & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KAVL | KPRX |
|---|---|---|
| Founded | 1998 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6M | 9.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | KAVL | KPRX |
|---|---|---|
| Price | $0.47 | $1.89 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 62.5K | 53.2K |
| Earning Date | 09-16-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,127,037.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.40 | $1.77 |
| 52 Week High | $1.55 | $4.18 |
Technical Indicators
Market Signals| Indicator | KAVL | KPRX |
|---|---|---|
| Relative Strength Index (RSI) | 41.41 | 35.67 |
| Support Level | $0.46 | $1.80 |
| Resistance Level | $0.50 | $1.99 |
| Average True Range (ATR) | 0.04 | 0.12 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 15.60 | 21.81 |
Price Performance
Historical ComparisonAbout KAVL Kaival Brands Innovations Group Inc.
Kaival Brands Innovations Group Inc is focused on growing and incubating creative and profitable products. The company is engaged in the sale, marketing and distribution of electronic nicotine delivery system (ENDS) products and related components. Its primary product includes Bidi Stick. The BIDI Stick comes in a variety of flavor options for adult cigarette smokers.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.